High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma

A literature-based meta-analysis

H. A. Azim, L. Santoro, Robert G Bociek, S. Gandini, R. A. Malek, H. A. Azim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Aggressive non-Hodgkin's lymphoma (NHL) represents ~60% of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Nevertheless, still a significant fraction of patients is not offered rituximab due to economic reasons. Thus, CHOP is still offered to these patients as well as those with T-cell subtypes. Data from the early 1990s have indicated that the dose intensity (DI) of doxorubicin is a key factor in predicting survival. Methods: A Medline and Cochrane library search was carried out using the search terms 'CHOP', 'lymphoma' and 'randomized trials'. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m 2 /week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95% confidence interval (CI) 0.71-0.96], event-free survival (SHR 0.86; 95% CI 0.75-0.99) and higher complete response rate (summary odds ratio 0.91; 95% CI 0.67-0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.

Original languageEnglish (US)
Pages (from-to)1064-1071
Number of pages8
JournalAnnals of Oncology
Volume21
Issue number5
DOIs
StatePublished - Oct 22 2009

Fingerprint

Non-Hodgkin's Lymphoma
Doxorubicin
Meta-Analysis
Confidence Intervals
Lymphoma
Survival
Vincristine
Prednisone
Cyclophosphamide
Libraries
Disease-Free Survival
B-Lymphocytes
Odds Ratio
Economics
T-Lymphocytes
Drug Therapy
Rituximab

Keywords

  • CHOP
  • Chemotherapy
  • Dose intensity
  • Doxorubicin
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma : A literature-based meta-analysis. / Azim, H. A.; Santoro, L.; Bociek, Robert G; Gandini, S.; Malek, R. A.; Azim, H. A.

In: Annals of Oncology, Vol. 21, No. 5, 22.10.2009, p. 1064-1071.

Research output: Contribution to journalArticle

Azim, H. A. ; Santoro, L. ; Bociek, Robert G ; Gandini, S. ; Malek, R. A. ; Azim, H. A. / High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma : A literature-based meta-analysis. In: Annals of Oncology. 2009 ; Vol. 21, No. 5. pp. 1064-1071.
@article{517c9af89bc84d5aa3e590df34abeb3e,
title = "High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: A literature-based meta-analysis",
abstract = "Background: Aggressive non-Hodgkin's lymphoma (NHL) represents ~60{\%} of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Nevertheless, still a significant fraction of patients is not offered rituximab due to economic reasons. Thus, CHOP is still offered to these patients as well as those with T-cell subtypes. Data from the early 1990s have indicated that the dose intensity (DI) of doxorubicin is a key factor in predicting survival. Methods: A Medline and Cochrane library search was carried out using the search terms 'CHOP', 'lymphoma' and 'randomized trials'. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m 2 /week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95{\%} confidence interval (CI) 0.71-0.96], event-free survival (SHR 0.86; 95{\%} CI 0.75-0.99) and higher complete response rate (summary odds ratio 0.91; 95{\%} CI 0.67-0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.",
keywords = "CHOP, Chemotherapy, Dose intensity, Doxorubicin, Non-Hodgkin's lymphoma",
author = "Azim, {H. A.} and L. Santoro and Bociek, {Robert G} and S. Gandini and Malek, {R. A.} and Azim, {H. A.}",
year = "2009",
month = "10",
day = "22",
doi = "10.1093/annonc/mdp425",
language = "English (US)",
volume = "21",
pages = "1064--1071",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma

T2 - A literature-based meta-analysis

AU - Azim, H. A.

AU - Santoro, L.

AU - Bociek, Robert G

AU - Gandini, S.

AU - Malek, R. A.

AU - Azim, H. A.

PY - 2009/10/22

Y1 - 2009/10/22

N2 - Background: Aggressive non-Hodgkin's lymphoma (NHL) represents ~60% of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Nevertheless, still a significant fraction of patients is not offered rituximab due to economic reasons. Thus, CHOP is still offered to these patients as well as those with T-cell subtypes. Data from the early 1990s have indicated that the dose intensity (DI) of doxorubicin is a key factor in predicting survival. Methods: A Medline and Cochrane library search was carried out using the search terms 'CHOP', 'lymphoma' and 'randomized trials'. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m 2 /week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95% confidence interval (CI) 0.71-0.96], event-free survival (SHR 0.86; 95% CI 0.75-0.99) and higher complete response rate (summary odds ratio 0.91; 95% CI 0.67-0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.

AB - Background: Aggressive non-Hodgkin's lymphoma (NHL) represents ~60% of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Nevertheless, still a significant fraction of patients is not offered rituximab due to economic reasons. Thus, CHOP is still offered to these patients as well as those with T-cell subtypes. Data from the early 1990s have indicated that the dose intensity (DI) of doxorubicin is a key factor in predicting survival. Methods: A Medline and Cochrane library search was carried out using the search terms 'CHOP', 'lymphoma' and 'randomized trials'. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m 2 /week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95% confidence interval (CI) 0.71-0.96], event-free survival (SHR 0.86; 95% CI 0.75-0.99) and higher complete response rate (summary odds ratio 0.91; 95% CI 0.67-0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.

KW - CHOP

KW - Chemotherapy

KW - Dose intensity

KW - Doxorubicin

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=77952242297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952242297&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp425

DO - 10.1093/annonc/mdp425

M3 - Article

VL - 21

SP - 1064

EP - 1071

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -